Agreement representative of Dario's channel-led growth strategy to bring cardiometabolic digital health solution at scale to self-insured employers seeking measurable reductions in cardiometabolic risk and total cost of care via payer relationships NEW YORK, July 6, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced a new agreement with a major health insurer with a stronghold in Arizona, entered into through its strategic channel partnership with Amwell. This opportunity makes Dario's cardiometabolic solution available to the insurer's Administrative Services Only ("ASO") book of business, representing access to hundreds of thousands of covered lives.
DarioHealth Corp.(DRIO)Earnings, Financials & Key Ratios
DRIO•NASDAQ
$7.08
5.7× P/E·Price updated Jul 7, 2026
AboutDarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.Show more
- Revenue$22M-17.3%
- EBITDA-$33M+34.2%
- Net Income-$42M+2.4%
- EPS (Diluted)1.24+267.6%
- Gross Margin56.64%+15.4%
- EBITDA Margin-148.02%+20.5%
- Operating Margin-163.94%+23.2%
- Net Margin-186.56%-18.0%
- ROE-59.62%+9.2%
DRIO Price & Volume
DarioHealth Corp. (DRIO) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Contraction Challenges Operational Viability
Investment Thesis • Updated 2026Q1
VerdictNegative: The company's ongoing cash burn
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Insufficient capital runway
Key Thesis Takeaways
- DarioHealth faces a precarious outlook as its strategic pivot to B2B channels has failed to arrest a 17.31% year-over-year revenue decline in 2026Q1.
- The company's inability to align its $8.1M SG&A expense base with its $5.6M quarterly revenue suggests a fundamental misalignment that threatens long-term solvency.
- Investors should remain cautious given the $57.4M in goodwill on the balance sheet and the persistent negative free cash flow trajectory that has now spanned ten consecutive quarters.
Verdict Logic
evidenced by a negative $6.0M operating cash flow in 2026Q1, combined with a 17.31% revenue decline, suggests significant liquidity risks that outweigh current valuation multiples.
DRIO Growth Metrics
DarioHealth Corp. (DRIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years39.13%
5 Years24.17%
3 Years-6.84%
TTM-24.41%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM239.99%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM1347.88%
Return on Capital
10 Years-198.13%
5 Years-70.73%
3 Years-53.11%
Last Year-36.11%
DRIO Recent Earnings
DarioHealth Corp. (DRIO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.81+25.7%
$1.09
Rev
$6M+2.3%
$5M
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$0.80+67.2%
$2.44
Rev
$5M+3.0%
$5M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$1.85+29.7%
$2.63
Rev
$5M-0.8%
$5M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$2.40-9.1%
$2.20
Rev
$5M-24.2%
$7M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.81vs $1.09+25.7% | $6Mvs $5M+2.3% |
| Q2 2026 | Mar 19, 2026 | $0.80vs $2.44+67.2% | $5Mvs $5M+3.0% |
| Q4 2025 | Nov 13, 2025 | $1.85vs $2.63+29.7% | $5Mvs $5M-0.8% |
| Q3 2025 | Aug 12, 2025 | $2.40vs $2.20-9.1% | $5Mvs $7M-24.2% |
Based on last 12 quarters of dataView full earnings history →
Latest DRIO News
Recent stock market news and headlines for DarioHealth Corp. (DRIO)
PRNewsWire·2 days ago
Dario Signs New Agreement with a Major Health Insurer in Arizona Representing Hundreds of Thousands of Lives Through Amwell PartnershipGuruFocus·5 days ago
Top National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Cardiometabolic Care, Demonstrating Successful Multi-Condition Growth StrategyTop National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Cardiometabolic Care, Demonstrating Successful
PRNewsWire·6 days ago
Top National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Cardiometabolic Care, Demonstrating Successful Multi-Condition Growth StrategyThird health plan customer to expand beyond initial deployment, reinforcing Dario's land-and-expand strategy and creating significant opportunity to grow revenue within existing customer base NEW YORK, July 2, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in AI-powered digital health solutions, today announced that one of the 5 largest health insurers in the U.S. has extended its initial agreement and expanded its relationship with Dario by adding the Company's hypertension solution, following success with Dario's behavioral health offering. The health plan's roll out of Dario's cardiometabolic care significantly increases the addressable population and has the potential to approximately triple Dario's revenue opportunity under this customer relationship.
PRNewsWire·Jun 30, 2026
Dario Appoints Former Humana Chief Compliance Officer Sean O'Reilly to Advisory Board to Support Strategic Growth and Healthcare PartnershipsO'Reilly's extensive experience across healthcare compliance, risk management, regulatory oversight and payer operations expected to support Dario's continued expansion with health plans, employers and providers as Dario moves closer to care O'Reilly's track record of leveraging advanced data analytics and AI in supporting value-based care strongly aligned with Dario's AI transition NEW YORK, June 30, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in AI-enabled digital health solutions, today announced the appointment of Sean O'Reilly to its Advisory Board. The appointment reflects Dario's continued focus on strengthening its strategic guidance as the Company advances its channel partner-led growth strategy and moves closer to care across the payer, provider and employer markets.
PRNewsWire·Jun 29, 2026
Dario Announces Strategic Collaboration with Beluga Health to Deliver Provider-Backed, Integrated Care at ScaleDario's best-in-class, consumer-centric chronic care platform, combined now with Beluga's embedded clinical delivery, extends member engagement to include provider-delivered treatment, lowering costs and expanding value for existing clients while opening large new markets NEW YORK, June 29, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in AI-powered digital health solutions, today announced it has entered into a Collaborative Services Agreement ("Agreement") with Beluga Health, P.A. ("Beluga"), establishing a strategic partnership to deliver a provider-backed, digitally-enabled model for longitudinal care, population health and quality improvement.
Peers Comparison
Key metrics vs top competitors for DarioHealth Corp. (DRIO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.08 | $351.39M | 5.71 | -17.31% | -186.56% | -59.62% | — | |
| $9.10 | $1.64B | -7.98 | -1.54% | -6.81% | -12.37% | — | |
| $44.36 | $2.02B | 1001.35 | 6.53% | 1.67% | 1.64% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $36.17 | $7.94B | 70.92 | 59% | -0.56% | -2.48% | — | |
| $73.57 | $28.39B | 35.20 | 15.6% | 19.31% | 33.83% | — |
Compare DRIO vs Peers
DarioHealth Corp. (DRIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DRIO SEC Filings & Documents
DarioHealth Corp. (DRIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
Apr 13, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Feb 2, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when DRIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DRIO Frequently Asked Questions
DarioHealth Corp. (DRIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is DarioHealth Corp.'s revenue?
DarioHealth Corp. (DRIO) reported $21.2M in revenue for fiscal year 2025.
How fast is DarioHealth Corp. growing?
DarioHealth Corp. (DRIO) saw revenue decline by 17.3% over the past year.
Is DRIO profitable?
Yes, DarioHealth Corp. (DRIO) is profitable, generating $62.7M in net income for fiscal year 2025 (-186.6% net margin).
Dividend & Returns
What is DRIO's return on equity?
DarioHealth Corp. (DRIO) has a return on equity (ROE) of -59.6%. Negative ROE indicates the company is unprofitable.
What is DarioHealth Corp.'s free cash flow?
DarioHealth Corp. (DRIO) had negative free cash flow of $25.4M in fiscal year 2025, likely due to heavy capital investments.